Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 13, 2007

Evotec Boosts Drug Discovery Business through Deal with Combinature

  • Evotec enhanced its fragment-based drug discovery business through the acquisition of certain assets from Combinature Biopharm. The company gained equipment and expertise in NMR screening and access to the SAR-by-NMR™ intellectual property, licensed from Abbott.

    Evotec thus will be able to integrate NMR-based screening technologies and the SAR-by-NMR technique with its high-throughput, high-concentration biochemical assay approach. The company believes this will augment solutions for its internal pipeline as well as offerings for partnering and collaborative research.

    The transaction also added a library of fragments, bringing the total up to 30,000, which Evotec states makes it the largest available fragment library from an independent fragment-based drug discovery firm.